Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

NCT06714955 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-diabetic Overweight or Obese

Interventions

DRUG: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
DRUG: Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
DRUG: Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.

Sponsor

BrightGene Bio-Medical Technology Co., Ltd.